WILMINGTON,Assets of Endeavor Pharmaceuticals will be sold for $35 million to Barr Laboratories of Woodcliff Lake, NJ, according to an asset purchase agreement the companies have reached.

In the transaction, Barr will acquire the New Drug Application (NDA) and intellectual property related to Endeavor’s Enjuvia synthetic conjugated estrogens product, and two early stage development female healthcare products.

“The pending acquisition of Enjuvia and the two early stage development products will enable Barr to broaden its line of hormone therapy and other female healthcare products,” said Bruce Downey, chairman and CEO of Barr. “We believe that Enjuvia, which is a patented synthetic conjugated estrogens product, will allow Barr to bring a new generation of products to American women electing to use hormone therapy.”

Enjuvia is a plant-derived, synthetic conjugated estrogen product that includes dehydroestrone sulfate, an additional active estrogenic component. Some studies suggest that it contributes to the relief of vasomotor symptoms experienced by menopausal women, including hot flashes, chills, burning or tingling sensations and sleep and mood disturbances.

Wilmington-based Endeavor filed its NDA for approval of Enjuvia with the FDA in March of 2002.

Endeavor: www.endeavorpharm.com